ARTICLE | Distillery Therapeutics
Neurology
July 18, 2017 8:58 PM UTC
Cell culture and mouse studies suggest an allosteric modulator of the mGluR5-PRNP interaction could help treat AD. In a transgenic mouse model of AD, oral 7.5 mg/kg daily doses for 4-5 weeks of a tool...
BCIQ Company Profiles